Andrew Dillin
Corporate Officer/Principal at University of California, Berkeley
Profile
Andrew Dillin is the founder of Proteostasis Therapeutics, Inc. (founded in 2006) and Mitobridge, Inc. (founded in 2013).
He is currently a Professor at the University of California, Berkeley.
Dr. Dillin earned a doctorate degree from the University of California, Berkeley.
Andrew Dillin active positions
Companies | Position | Start |
---|---|---|
University of California, Berkeley | Corporate Officer/Principal | - |
Former positions of Andrew Dillin
Companies | Position | End |
---|---|---|
Mitobridge, Inc.
Mitobridge, Inc. BiotechnologyHealth Technology Mitobridge, Inc. operates as a biopharmaceutical company. It focuses on the development and discovery of products for mitochondrial function. The firm also offers treatments for genetic, metabolic, and neurodegenerative disorders as well as diseases and conditions of aging. The company was founded by Kazumi Shiosaki, Andrew Dillin, Ronald M. Evans, Johan Auwerx and Robert H. Horvitz in October 2011 and is headquartered in Cambridge, MA. | Founder | - |
PROTEOSTASIS THERAPEUTICS, INC. | Founder | - |
Training of Andrew Dillin
University of California, Berkeley | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |
Mitobridge, Inc.
Mitobridge, Inc. BiotechnologyHealth Technology Mitobridge, Inc. operates as a biopharmaceutical company. It focuses on the development and discovery of products for mitochondrial function. The firm also offers treatments for genetic, metabolic, and neurodegenerative disorders as well as diseases and conditions of aging. The company was founded by Kazumi Shiosaki, Andrew Dillin, Ronald M. Evans, Johan Auwerx and Robert H. Horvitz in October 2011 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Andrew Dillin